| Biotechnology Industry | Healthcare Sector | Benjamin Kaplan CEO | OTC PINK Exchange | 62846W107 CUSIP |
| US Country | 1 Employees | - Last Dividend | - Last Split | - IPO Date |
Aibotics Inc., along with its subsidiaries, focuses on the exploration and study of psychedelics aimed at treating various mental health disorders in the United States. This innovative company specializes in the development of psychedelic methodologies targeted towards alleviating conditions such as palliative care challenges, depression, and anxiety. Originally known as Mycotopia Therapies, Inc., the company rebranded to Aibotics Inc. in February 2025. The corporate headquarters are located in Miami, Florida, propelling Aibotics as a vital entity in the burgeoning field of psychedelic therapy.
Aibotics Inc. offers comprehensive treatment methodologies designed to utilize psychedelics in addressing major depressive disorders. These innovative therapies aim to provide patients with sustainable relief, harnessing the unique properties of psychedelics to facilitate profound psychological healing.
The company develops and implements specialized programs focusing on the use of psychedelics as therapeutic agents to reduce anxiety symptoms. Aibotics employs evidence-based practices to ensure that their methodologies yield effective outcomes for individuals struggling with anxiety-related disorders.
Aibotics innovates treatments that integrate psychedelic experiences into palliative care, providing comfort and emotional support to patients facing terminal illnesses. The aim is to enhance the quality of life and alleviate psychological distress for both patients and their families.
The company actively engages in research programs aimed at understanding the therapeutic potential of various psychedelics. By collaborating with academic institutions and health organizations, Aibotics contributes to the growing body of knowledge surrounding psychedelic applications in mental health.
Aibotics recognizes the importance of supporting patients through their therapeutic journey. They provide access to counseling and recovery resources tailored to individual needs, ensuring that each patient benefits fully from psychedelic treatments while maintaining safety and efficacy.